RxDoctor Payments Data

Dirk Juschka, MD

Family Medicine · Westerville, OHNPI 1497750137

Payments from drug & device makers

$828in general payments, 2019–2025

Across 18 payments — averaging $46.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$307
  • Teva Pharmaceuticals USA, Inc.$155
  • E.r. Squibb & Sons, L.L.C.$122
  • Acadia Pharmaceuticals Inc$90
  • Avanir Pharmaceuticals, Inc.$56
  • AstraZeneca$49
  • plus $50 from 2 others

What the payments were for

  • Food & beverage$828100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$828 in reported general payments places this provider in the 60th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$13,503
Medicare patients
67
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,769$857,456
Invega SustennaPaliperidone Palmitate162$546,207
TrulicityDulaglutide403$253,248
IngrezzaValbenazine Tosylate50$222,374
XareltoRivaroxaban715$220,369
JardianceEmpagliflozin615$211,600
NuedextaDextromethorphan Hbr/Quinidine171$146,591
JanuviaSitagliptin Phosphate405$118,201
OzempicSemaglutide100$101,889
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog535$99,275
EntrestoSacubitril/Valsartan287$99,173
Divalproex Sodium1,555$88,669
XifaxanRifaximin64$84,489
Trelegy ElliptaFluticasone/Umeclidin/Vilanter136$83,624
TradjentaLinagliptin264$71,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$56$146,591171 claims
AstraZenecaFarxiga$49$67,112222 claims
Otsuka America Pharmaceutical, Inc.Rexulti$307$56,68376 claims
Acadia Pharmaceuticals IncNuplazid$90$42,17615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →